{"sequenceId":"845363545315","id":"34207155292","language":"English","title":"Head to Head Comparison: arGEN-X BV (ARGX) & Adaptimmune Therapeutics (ADAP)","content":"Adaptimmune Therapeutics (NASDAQ: ADAP) and arGEN-X BV (NASDAQ:ARGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.    Institutional & Insider Ownership    Get Adaptimmune Therapeutics alerts:      60.0% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 52.4% of arGEN-X BV shares are held by institutional investors. 26.5% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.      Analyst Ratings    This is a summary of current recommendations and price targets for Adaptimmune Therapeutics and arGEN-X BV, as reported by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  Adaptimmune Therapeutics  0  0  4  0  3.00  arGEN-X BV  0  0  5  0  3.00   Adaptimmune Therapeutics currently has a consensus target price of $17.67, indicating a potential upside of 31.45%. arGEN-X BV has a consensus target price of $101.00, indicating a potential upside of 6.11%. Given Adaptimmune Therapeutics’  higher possible upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than arGEN-X BV.    Profitability    This table compares Adaptimmune Therapeutics and arGEN-X BV’s net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  Adaptimmune Therapeutics  -160.83%  -32.57%  -24.93%  arGEN-X BV  N/A  N/A  N/A   Valuation & Earnings    This table compares Adaptimmune Therapeutics and arGEN-X BV’s gross revenue, earnings per share (EPS) and valuation.    Gross Revenue  Price/Sales Ratio  Net Income  Earnings Per Share  Price/Earnings Ratio  Adaptimmune Therapeutics  $37.83 million  33.45  -$70.13 million  ($0.80)  -16.80  arGEN-X BV  $44.74 million  68.44  -$31.73 million  ($1.40)  -67.99   arGEN-X BV has higher revenue and earnings than Adaptimmune Therapeutics. arGEN-X BV is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.    Summary    arGEN-X BV beats Adaptimmune Therapeutics on 7 of the 12 factors compared between the two stocks.    Adaptimmune Therapeutics Company Profile    Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.    arGEN-X BV Company Profile    argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.","contentWithMarkup":"Adaptimmune Therapeutics (NASDAQ: ADAP) and arGEN-X BV (NASDAQ:ARGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.    Institutional & Insider Ownership    Get Adaptimmune Therapeutics alerts:      60.0% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 52.4% of arGEN-X BV shares are held by institutional investors. 26.5% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.      Analyst Ratings    This is a summary of current recommendations and price targets for Adaptimmune Therapeutics and arGEN-X BV, as reported by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  Adaptimmune Therapeutics  0  0  4  0  3.00  arGEN-X BV  0  0  5  0  3.00   Adaptimmune Therapeutics currently has a consensus target price of $17.67, indicating a potential upside of 31.45%. arGEN-X BV has a consensus target price of $101.00, indicating a potential upside of 6.11%. Given Adaptimmune Therapeutics’  higher possible upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than arGEN-X BV.    Profitability    This table compares Adaptimmune Therapeutics and arGEN-X BV’s net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  Adaptimmune Therapeutics  -160.83%  -32.57%  -24.93%  arGEN-X BV  N/A  N/A  N/A   Valuation & Earnings    This table compares Adaptimmune Therapeutics and arGEN-X BV’s gross revenue, earnings per share (EPS) and valuation.    Gross Revenue  Price/Sales Ratio  Net Income  Earnings Per Share  Price/Earnings Ratio  Adaptimmune Therapeutics  $37.83 million  33.45  -$70.13 million  ($0.80)  -16.80  arGEN-X BV  $44.74 million  68.44  -$31.73 million  ($1.40)  -67.99   arGEN-X BV has higher revenue and earnings than Adaptimmune Therapeutics. arGEN-X BV is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.    Summary    arGEN-X BV beats Adaptimmune Therapeutics on 7 of the 12 factors compared between the two stocks.    Adaptimmune Therapeutics Company Profile    Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.    arGEN-X BV Company Profile    argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.","tags":[],"publishedDate":"2018-06-03T03:31:00Z","harvestDate":"2018-06-02T21:35:23Z","estimatedPublishedDate":"2018-06-02T21:35:23Z","url":"http://ct.moreover.com/?a=34207155292&p=1u0&v=1&x=-Zx7Uf3eEfcxQ6vhMSIv0A","originalUrl":"https://ledgergazette.com/2018/06/02/contrasting-argen-x-bv-argx-adaptimmune-therapeutics-adap-3.html","outboundUrls":[],"wordCount":"685","dataFormat":"text","duplicateGroupId":"34207155292","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Business latest","group":"Business"}],"companies":[{"name":"Adaptimmune Therapeutics PLC","symbol":"ADAP","exchange":"NAS","isin":"US00653A1079","titleCount":1,"contentCount":20,"primary":true},{"name":"Adaptimmune Therapeutics PLC","symbol":"473A","exchange":"FRA","isin":"US00653A1079","titleCount":1,"contentCount":20,"primary":true},{"name":"Adaptimmune Therapeutics PLC","symbol":"473A","exchange":"STU","isin":"US00653A1079","titleCount":1,"contentCount":20,"primary":true},{"name":"Adaptimmune Therapeutics PLC","symbol":"473A","exchange":"BER","isin":"US00653A1079","titleCount":1,"contentCount":20,"primary":true},{"name":"argenx SE","symbol":"1AE","exchange":"BER","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"ARGX","exchange":"BRU","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"ARGNF","exchange":"PINX","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"0QW0","exchange":"LTS","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"ARGX","exchange":"NAS","isin":"US04016X1019","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"1AE","exchange":"STU","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"argenx SE","symbol":"1AE","exchange":"FRA","isin":"NL0010832176","titleCount":0,"contentCount":2,"primary":false},{"name":"GlaxoSmithKline","symbol":"BIOC","exchange":"CAI","isin":"EGS38171C012","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7A","exchange":"HAM","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"HAM","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"MUN","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"FRA","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7A","exchange":"BER","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7A","exchange":"FRA","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"BER","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"DUS","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"STU","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7A","exchange":"MUN","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"ETR","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7A","exchange":"ETR","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GSK","exchange":"NYS","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GLAXF","exchange":"PINX","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GSK N","exchange":"MEX","isin":"US37733W1053","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GSK","exchange":"BUE","isin":"ARDEUT110483","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GS7","exchange":"HAN","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GSK","exchange":"LON","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"GlaxoSmithKline PLC","symbol":"GSK","exchange":"SWX","isin":"GB0009252882","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"FRA","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"STU","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"DUS","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"MUN","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"HAN","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"BER","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"HAM","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"SWX","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"PAR","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"6MK","exchange":"ETR","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"NYS","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"BSE","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"SGO","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"MEX","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRCK34","exchange":"BSP","isin":"BRMRCKBDR003","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"BUE","isin":"ARDEUT110277","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"0QAH","exchange":"LTS","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false},{"name":"Merck & Co Inc","symbol":"MRK","exchange":"WBO","isin":"US58933Y1055","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Sebastian Weber","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Ledger Gazette","homeUrl":"https://ledgergazette.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"599564993","name":"Ledger Gazette","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1137"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Business"],"genre":"General"}},"es_id":86991820}